Skip to main content
. Author manuscript; available in PMC: 2018 Jun 15.
Published in final edited form as: Bioorg Med Chem. 2017 Nov 10;25(24):6707–6717. doi: 10.1016/j.bmc.2017.11.015

Fig. 4.

Fig. 4

(A) Schematic representation of the tandem activation of prodrug 16 beginning with cleavage of PSA substrate by PSA followed by intracellular dipeptide cleavage and spontaneous release of emetine; (B) Cleavage of the PSA substrate in prodrug 16 to liberate precursor 14 measured over 20 h; (C) Concentration dependent cytotoxicity studies of prodrug 16 in different prostate cancer cell lines; (D) Concentration dependent cytotoxicity studies of emetine in different prostate cancer cell lines to provide a simple comparison with prodrug 16 (Fig. 4C).